RNS Number : 8806T Renalytix PLC 17 November 2023 Renalytix plc ("Renalytix" or the "Company") Publication of Annual Report 2023 and Notice of 2023 Annual General Meeting LONDON and SALT LAKE CITY, UT November, 17 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Annual
LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today
RNS Number : 3099T Renalytix PLC 14 November 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024 LONDON and SALT LAKE CITY , November 14, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live
RNS Number : 5522S Renalytix PLC 07 November 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14 LONDON and SALT LAKE CITY , November 7, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it
RNS Number : 7470R Renalytix PLC 30 October 2023 Renalytix plc ("Renalytix" or the "Company") Announcement of AGM and Publication of Annual Report 2023 LONDON and SALT LAKE CITY, UT October 30, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Annual General Meeting
RNS Number : 0376R Renalytix PLC 24 October 2023 Renalytix plc ("Renalytix" or the "Company") Directorate change LONDON and SALT LAKE CITY - October 24, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) , the first company to commercialize an FDA authorized artificial intelligence (AI)
RNS Number : 3030Q Renalytix PLC 17 October 2023 Renalytix plc ("Renalytix" or the "Company") Issue of Shares LONDON and SALT LAKE CITY - October 17, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) , announces the repayment of $1.06 million of the Company's convertible bond, further
LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and
RNS Number : 8892O Renalytix PLC 06 October 2023 Renalytix plc ("Renalytix" or the "Company") US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix LONDON and SALT LAKE CITY - October 6, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the